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Abstract
Background: Rice protein is proved to have hypocholesterolemic and anti-atherosclerotic effects, and a few
experimental studies showed its renoprotective effects, using animal diabetic models. However, no clinical
studies have investigated its benefits for human health. We aimed to clarify how the intake of rice endosperm protein
affects markers correlating to lipid dysfunction in human.
Methods: We recruited 18 male volunteers, 26–64 years of age, with risk factors for metabolic syndrome and allocated
randomly into two groups. Half of them were administered test food containing rice endosperm protein and
other half were administered control food containing sodium caseinate for 4 weeks. The dose of supplemental
protein was 10 g/day. After medical examinations, the study foods were switched and the intervention was
continued for another 4 weeks. Lipid metabolism markers were evaluated as primary outcome measures. Cross-over
analysis was performed for 18 subjects using physical and clinical values measured before and after each intervention
period.
Results: The serum high-density lipoprotein cholesterol (HDL-C) level was increased at 0.08 mmol/L [interquartile
range (IQR) from −0.05 to 0.19 mmol/L] during the period when rice endosperm protein was administered (the
rice endosperm protein period), whereas it was decreased at −0.04 mmol/L [IQR from −0.13 to 0.05 mmol/L]
during the period when casein was administered (the casein period). Treatment effect was significant with P = 0.047.
Changes in total cholesterol, low-density lipoprotein cholesterol and triglycerides were not different between
treatments. Among the secondary outcome measures, decrease in serum uric acid (UA) during the rice endosperm
protein period [−24 μmol/L (IQR from −39 to −6 μmol/L)] was greater than that during the casein period [0 (IQR from
−6 to 13 μmol/L)] with a significant treatment effect (P = 0.030).
Conclusion: Supplemental intake of rice endosperm protein may elevate serum HDL-C level and lower serum UA level
in male subjects with risk factors for metabolic syndrome.
Trial registration: Clinical Trials Registry: UMIN000008923.
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Background
Lifestyle habits, such as unhealthy eating, cause or
exacerbate health problems, although predisposition to
life style related diseases may be determined by genetic
factors. A recent survey in Japan estimated that ap-
proximately 10.7 million patients suffer from the meta-
bolic syndrome, and that 9.4 million people are at the
risk of developing it. The prevalence of the metabolic
syndrome is particularly striking in adult men aged
40–74 years. In this population, one in two men is
either currently suffering from or is at the risk of de-
veloping metabolic syndrome [1]. Individuals suffering
from metabolic syndrome have a 5-fold increased risk
of developing diabetes, and those with diabetes have a
2- to 5-fold increased risk of developing cardiovascular
disease [2]. Therefore, measures taken to reduce the risk
of developing metabolic syndrome, such as the improve-
ment of dietary habits, are considered to be important.
The increased prevalence of metabolic syndrome and con-
sequent higher risk for cardiovascular disease are thought
to be due to obesity and insulin resistance influenced by
lifestyle and western dietary pattern, such as increased
energy, sugar, saturated fatty acid, less fiber, less physical
activity, etc. Although rice remains the major nutrient
source in Japanese diet, its consumption was halved be-
tween 2012 and peaked in 1962 [3]. The reduction in rice
consumption in Japan is thought to be due at least a part
to the westernization of dietary habit. However, Eshak et
al. demonstrated the negative correlation between the
amount of rice intake and the risk of cardiovascular
disease in Japanese men [4]. Similarly, white rice intake in
the way it is consumed in Southern Spain is reported to
be negatively associated to the 6 years incidence of type 2
diabetes [5]. These findings suggest the beneficial effect of
rice consumption under certain circumstances.
In animal trials, we and another group have shown
that purified rice endosperm protein have hypocholester-
olemic effects [6, 7]. Similarly, Tong et al. demonstrated
that α-globulin, a component of rice endosperm protein,
decreased serum cholesterol concentrations in rats fed a
hypercholesterolemic diet and ameliorated atheroscler-
otic lesions in apolipoprotein (Apo) E-deficient mice [8].
These findings suggest the beneficial effects of rice endo-
sperm protein intake in ameliorating lipid dysfunction
such as decreasing total cholesterol (TC), low density
lipoprotein cholesterol (LDL-C) and triglycerides (TG).
Moreover, we reported that rice endosperm protein
minimized the progression of diabetic nephropathy in
Goto-Kakizaki rats on high-sucrose diet [9]. These find-
ings encouraged us to clarify the effects of endosperm
protein from white rice in humans with respect to risks
for metabolic syndrome and cardiovascular disease.
In addition to rice protein, soy protein is another
source of vegetable protein. Many studies have reported
the health benefits of soy protein. The efficacy of soy
protein intake on lowering the risk of coronary heart
disease has been accepted by the US Food and Drug
Administration [10]. Consumption of soy protein signifi-
cantly lowers cardiovascular risks by affecting fasting
plasma glucose, TC, LDL-C, serum TG, and C-reactive
protein [11], and soy protein supplementation is thought
to be an effective management strategy for metabolic
and vascular diseases [12]. However, much less is known
regarding the health benefits of rice protein. Using our
method for the preparation of food grade purified rice
endosperm protein from white rice, we aim to perform
exploratory study to clarify how the intake of rice endo-
sperm protein affects markers correlating to lipid dysfunc-
tion in humans as the primary clinical outcomes and
those relating to metabolic syndrome risk factors. Our
study is the first human trial of rice endosperm protein




Adults were recruited among working people in Co-op
Chemical Co., Ltd., Niigata, Japan who have the annual
medical checkup based on the checked-up records ob-
tained in April 2012. The study included subjects with at
least two of the following criteria for the clinical diagno-
sis of metabolic syndrome according to the modified
National Cholesterol Education Program’s Adult Treat-
ment Panel III (NCEP): (i) visceral fat obesity defined as
waist circumference ≥ 90 cm, (ii) serum TG ≥ 1.7 mmol/L
or on drug treatment for elevated TG, (iii) serum high-
density lipoprotein cholesterol (HDL-C) < 1.03 mmol/L or
on drug treatment for reduced HDL-C, (iv) systolic-
blood pressure (SBP) ≥ 130 mmHg, diastolic-blood pres-
sure (DBP) ≥ 85 mmHg, or use of antihypertensive drugs,
and (v) fasting plasma glucose ≥ 5.6 mmol/L or on drug
treatment for elevated glucose [13]. Practically, among
these criteria, “on drug treatment for reduced HDL-C”
was not applicable for this study because such treatment
is not permitted in the Japanese medical insurance system.
The exclusion criteria were as follows: 1) current treat-
ment for diabetes mellitus, 2) severe heart, renal or liver
disease, 3) perioperative stages, or severe infection or
serious injury, 4) food allergies, and 5) those not eligible
for the study due to any medical reason evaluated by a
physician.
Study design and enrollment
The prospective, randomized, single blind, crossover study
took place from September to December 2012. The sub-
jects approved to participate in the trial were enrolled.
Subjects were alternately assigned by the chief attending
doctor according to the order of enrollment to any of the
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rice endosperm protein first group or the casein first
group, respectively. Therefore, participants were blinded
while chief attending doctor was not. During the pre-
observation period, the subjects underwent physical ex-
aminations, including waist circumference, body mass
index (BMI), SBP, DBP, and laboratory tests. Blood sam-
ples were obtained by venipuncture, reserved in collection
tubes and centrifuged immediately at 1,700 × g for 15 min
at 4 °C to recover serums. Biochemical analyses were
performed by SRL, Inc. (Tokyo, Japan), a certified la-
boratory by the College of American Pathologists, an
authoritative external organization, and the Japan Ac-
creditation Board for Conformity Assessment started
(ISO15189), an international standards for clinical test-
ing laboratories. HDL-C levels were measured using the
direct assay (Sekisui medical Inc., Japan). Uric acid
(UA) levels were assayed by enzymatic methods (Sekisui
medical Inc., Japan). Monocyte chemoattractant protein-1
(MCP-1) levels were measured using the ELISA assay
(R&D SYSTEMS, Minneapolis). The mean coefficient of
variation of HDL-C, UA, and MCP-1 measurements were
inquired to be less than 5 %, less than 3 %, and 4.6–7.8 %,
respectively. Waist circumference was measured at the
umbilical level in the standing position after light expir-
ation using a measuring tape, and BMI was calculated as
weight divided by height squared. Blood pressure was
measured once with an automatic sphygmomanometer
while the patient was seated and after 5 min of rest. These
examinations were performed in fasting condition.
Intervention
The test or control food, after being suspended in hot or
cold water, was given twice a day to the subjects. The
daily amount of supplemental protein to usual meal was
calculated to be 10 g in total. No dietary habit restrictions
were instructed during the trial period. The enrolled
subjects were instructed to not change their lifestyle or
physical activities during the study. After the second
medical check at the end of week 4, the intervention foods
were switched after 3 days of washout, and the test was
pursued for another 4 weeks. Namely, the rice endosperm
protein was administered for the rice endosperm protein
first group during the first 4 weeks (period 1), and for the
casein first group during the last 4 weeks (period 2),
respectively (the rice endosperm protein period), whereas
casein was administered for these groups during periods 2
and 1, respectively (the casein period).
Follow-up
Consumption of intervention food and occurrence of
adverse events were examined by attending doctors
based on the individuals’ study diary. Lifestyle and
medicating situation of each subject was checked using
a self-reporting sheet. Dietary habits were assessed using a
validated, brief-type self-administered, diet history ques-
tionnaires (BDHQ), at the beginning and end of the inter-
ventional study [14]. Details of the BDHQ’s structure,
calculation method of dietary intake, and validity for
commonly studied macronutrients intake have been
published [15]. Although the reliability of absolute values
of energy intake has not been validated, we described the
statistics of energy intake along with those of macronutri-
ents to warrant that dietary habits of the subjects were not
significantly altered during the study period. Subjects were
followed-up for a month after the final medical investiga-
tion at the end of week 8, and the test was completed at
the end of December 2012.
Preparation of test and control foods
Rice endosperm protein was extracted from rice flour of
regular Japonica rice, Koshihikari by the alkaline extrac-
tion method described by Kumagai et al. [16]. The pro-
duction was performed in a test plant set in Kameda
Seika Co. Ltd. (Niigata, Japan) and was expanded to a
100-times larger scale than that described, and the pro-
tein was heated at 80 °C for 30 min before lyophilization.
The rice endosperm protein powder with a 90.5 % protein
content (calculated from the nitrogen content using a pro-
tein/nitrogen coefficient as 5.95) and Sodium Caseinate
CW® (Nippon Shinyaku, Kyoto, Japan, 88.7 % protein con-
tent) were used as protein sources for test food and
control food, respectively. Compositions of these dietary
protein materials are summarized in Table 1. Their typical
amino acid compositions quoted from Kubota et al. [9]
are also shown in Table 1. Dextrin MAX 1000® was ob-
tained from Matsutani Chemical Industry, Itami, Japan,
and SK SWEET Z-3-15® (glucosylated stevia sweetener)
was purchased from Nippon paper industries, Tokyo,
Japan. The composition of the intervention food is shown
in Table 2. These intervention foods were almost the same
powder configurations, colors, tastes, and smells. They
were packed in an aluminum bag and heat sealed.
Evaluation of outcome
Lipid metabolism markers such as serum TC, HDL-C,
subfractions of HDL-C (HDL2 and HDL3), ApoA1,
ApoA2, ApoB, ApoC2, ApoC3, ApoE, oxidized LDL
(ox-LDL), remnant-like lipoprotein cholesterol (RLP-C),
LDL-C, and TG were evaluated as primary outcome mea-
sures. Urea nitrogen (UN), UA, creatinine (CRE), insulin,
adiponectin, glucose, high sensitive C-reactive protein
(hsCRP), and MCP-1 of serum samples were measured as
secondary outcomes. Fundamental values of hepatic and
uric markers were also evaluated. These measurements
were performed before and after each 4-week intervention
period.
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Evaluation of safety
Tolerability and safety were evaluated on the basis of
the incidence and severity of the study of food-related
adverse events experienced throughout the study. All
adverse events occurring in both groups were analyzed
for their frequency, severity, and association with inter-
vention and efficacy outcome.
Statistics
Because many outcome measures were not normally
distributed when the distribution was tested using the
Kolmogolov–Smirnov test, we applied nonparametric
analyses except for descriptive statistics for which values
are expressed as means ± standard deviation (SD) for con-
venience. Change in values over time was tested using the
Wilcoxon signed-rank test; change values were expressed
in median [inter-quartile range]. Crossover analyses for
treatment effect and treatment-period interaction were
performed in accordance with the methods described in
the textbook of Armitage and Berry [17]. Briefly, an abso-
lute change in each outcome measure was calculated for
each individual for each of period 1 and period 2 as d1
and d2, respectively. Then, the treatment effect was tested
by comparing (d1 – d2) between the rice endosperm pro-
tein first and the casein first groups, and the treatment-
period interaction was tested by comparing (d1 + d2)
between the two groups. Although Student’s t-test is
recommended to analyze these effects in the textbook, we
applied Mann–Whitney U-test because we needed to con-
sider non-parametric statistical procedures as mentioned
above. Statistical analysis was performed using a statistical
add-in software of Excel (Statcel 3, OMS Publishing,
Saitama, Japan) for MS Excel (Microsoft, Redmond, WA,
U.S.A.). Two-tailed P < 0.05 was regarded as statistically
significant and 0.05 ≤ P < 0.1 was considered to be border-
line level of statistical significance.
Results
Enrolled subjects and intervention
Twenty-four male subjects satisfying the inclusion criteria
approved to be enrolled. No female subjects approved to
participate in our study, although we wanted to recruit
both men and women. Two subjects with extremely high
serum TG levels (>9 mmol/L) were precluded. During the
intervention, 2 subjects had changed their lifestyle drastic-
ally, i.e., transferred from shift work to office clerk work.
Two subjects were found to have violated the instructions.
Consequently, the analysis was conducted for the 18
remaining subjects as shown in Fig. 1. Eight subjects on a
statin (HMG-CoA reductase inhibitor) for their elevated
cholesterol and continued with the medication throughout
the study.
Characteristics of subjects
Baseline characteristics of the 18 subjects were as follows,
age, 49.3 ± 10.6; height, 171.4 ± 6.6; body weight (BW),
74.8 ± 11.2; BMI, 25.3 ± 2.2; and waist circumference, 91.4
± 6.6. Five out of 18 subjects were diagnosed with meta-
bolic syndrome. Table 3 shows the dietary characteristics
of the 18 subjects. No significant differences in dietary
energy intake, percent energy of macronutrients, and ratio
of plant-to-animal protein balance were observed between
pre- and post-intervention values assessed using BDHQ.
During the 8-week intervention and follow-up period, no
adverse events were detected in any subjects enrolled.
Table 2 Composition of intervention foods
Test food Control food
Rice endosperm protein powder 5.5 −
Sodium caseinate − 5.5
Dextrin 5.17 5.17
Stevia sweetener 0.33 0.33
Values are indicated in g/package. Subjects were administered two packages
per day after suspending in cold or hot water
Table 1 Composition of the rice endosperm protein and
sodium caseinate








Dietary fiber <0.1 <0.1
Ash 1.5 3.5
Na (mg/100 g) 5 1200
Amino acids (μmol/mg protein)
Asp + Asn 0.73 0.55
Thr 0.31 0.36
Ser 0.55 0.58
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Effects of rice endosperm protein intake
Effects of rice endosperm protein intake on physical
measurements and clinical parameters were compared
with those of casein intake. Results are shown in Table 4.
Treatment-period interactions were checked and were
not detected for any variables (data not shown).
Among the parameters related to the criteria for the
clinical diagnosis of metabolic syndrome, no significant
treatment effect was observed for waist circumference,
SBP, DBP, glucose, and TG. On the other hand, HDL-C
was influenced by the type of supplemental protein.
HDL-C levels significantly increased during the rice endo-
sperm protein period whereas it did not during the casein
period; and this increase was considerably greater with a
statistically significant treatment effect (P = 0.047). In
contrast, no significant differences were observed in TC,
LDL-C, HDL2, HDL3, ApoA1, ApoA2, ApoB, ApoC2,
ApoC3, ApoE, ox-LDL, or RLP-C.
Serum UA was significantly reduced during the rice
endosperm protein period, while this level did not change
during the casein period. Presence of treatment effect was
also confirmed by crossover analysis with P = 0.030. Slight
increase in CRE, and slight decrease in ox-LDL were seen
in both groups and these changes were statistically signifi-
cant in the casein period. However, no significant treat-
ment effects were found at all (Table 4). Serum MCP-1
levels were significantly reduced during the rice endo-
sperm protein period (P < 0.01) while not during the
casein period: the treatment effect was not significant but
reached to the borderline significance level (P = 0.058).
DBP was considerably increased during the intervention
period irrespective of the type of supplemental protein.
Fig. 1 Flow diagram of subjects
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However, no significant treatment effect was observed.
Hepatic and urinary parameters were also analyzed, but
no significant changes were observed (data not shown).
Discussion
We conducted the first human trial to clarify the benefi-
cial effect of rice endosperm protein intake in adult male
subjects with risk factors for metabolic syndrome. Some
animal experiments have been performed and the effect
of rice endosperm protein in ameliorating lipid profile in
humans was expected. Consequently biomarkers related
to lipid metabolism were evaluated as main outcomes.
The present study was performed as an exploratory one,
consequently, variables somewhat different between the
rice endosperm protein and the casein periods were also
discussed even without statistical significance.
The administration of proteins (rice endosperm pro-
tein or casein) at a dose of 10 g protein/day during four
consecutive weeks did not affect TG, LDL-C, HDL2,
HDL3, ApoA1, ApoA2, ApoB, ApoC2, ApoC3, ApoE,
ox-LDL, or RLP-C. However, HDL-C was significantly
influenced by the type of ingested protein, particularly
rice endosperm protein significantly increased HDL-C
during the intervention (Table 4). Diet mediated incre-
ment of HDL-C is summarized in a review of Kapur
et al. [18]. However, the effects of dietary proteins
and a correlation with HDL-C levels are poorly investi-
gated. Egg white is reported to elevate HDL-C in rodents
[19] and humans [20]. Oda [21] mentioned in his review
that sulfur-containing amino acids, especially methionine,
were responsible for the increase in HDL-C and ApoA1.
Rice endosperm protein is known to contain a higher level
of sulfur-containing amino acids than casein and soy pro-
tein [7], at a level comparable to that of egg white. The
human trial reporting the elevation of HDL-C levels with
the administration of egg white [20] used a protein supply
of 23 g daily, an amount of protein much greater than that
in our study. However, elevation in HDL-C levels by rice
endosperm protein intake might, at least in part, be ex-
plained by the stimulation of APOA1 by sulfur-containing
amino acids in rice endosperm protein [21], although no
significant differences other than HDL-C were observed.
We previously reported studies conducted in normal
adult Wistar rats fed a normal diet, growing rats fed a
cholesterol-enriched diet [7], or non-obese diabetic rats
fed a high-sucrose diet showing a reduction of TC [9] by
rice endosperm protein administration. The phenotypes
of outcome of rice endosperm protein intake in humans
and rodents were different in terms of changing lipid
metabolism. Low levels of HDL-C are reported to
increase the risk of coronary events in epidemiological
[22] and clinical studies [23]. However, drugs increasing
HDL-C levels such as fibrates, niacin, and cholesteryl
ester transfer protein inhibitor have failed to reduce the
risk of major cardiovascular events [24–28]. Further
studies are needed to test whether increased ApoA1
and HDL-C by rice endosperm protein demonstrate
cardiovascular protective properties.
Recent studies demonstrated that hyperuricemia is
linked not only to gout but also to other important
disorders including hypertension, chronic kidney disease,
cardiovascular disease, and metabolic syndrome [29]. Prior
to considering a drug treatment for symptoms, adopting a
progressive life style change such as healthier eating habits
is considered important for the prevention and treatment
of hyperuricemia [30]. Along with such a trend, new food
ingredients with hypouricemic effect are being researched.
The methanol extract of a fruit [31], a flavonoid from a
traditional herb [32], and onion [33] are demonstrated as
hypouricemic substances by animal studies. The hypouri-
cemic effect of fermented barley extract was shown in a
human study reported by Hokazono et al. [34]. How-
ever, information on such effect in food and foodstuff
remains limited. We have demonstrated in the present
trial that rice endosperm protein intake significantly
decreased serum UA levels compared with serum UA
levels associated with casein intake. While ingested rice
endosperm protein reduces serum UA, the responsible
protein molecule remains to be identified and is cur-
rently investigated.
Intake of rice endosperm protein was found in the
present study to decrease significantly the serum MCP-1
level, while casein intake did not change it. MCP-1, a
secreted protein specifically attracting blood monocytes
and tissue macrophages, is known to correlate with in-
flammation, and the increased level of serum MCP-1 is
associated with markers of metabolic syndrome, obesity,
insulin resistance, type 2 diabetes, hypertension, and
hyperlipidemia [35]. Soy protein consumption is reported
Table 3 The energy and nutrients intake from usual meals at
the beginning and end of the study
Variables Baseline Week 8
Energy (MJ/day) 9.17 ± 2.10 9.65 ± 3.45
Carbohydrate (%E) 52.4 ± 6.9 52.2 ± 5.7
Fat (%E) 25.3 ± 4.3 24.8 ± 4.2
Protein (%E) 14.1 ± 2.7 14.1 ± 2.3
(g/kg BW) 1.05 ± 0.35 1.11 ± 0.47
Animal proteina (%) 57.8 ± 9.5 57.8 ± 6.7
Plant proteinb (%) 42.2 ± 9.5 42.2 ± 6.7
Alcohol (%E) 6.5 ± 6.1 7.3 ± 6.4
Number of subjects were 18. Dietary intake was assessed by BDHQ. Protein
intake does not include supplemental protein for the study. Values are
indicated as means ± SD
aProteins from the following food groups were included in animal protein: fish
and shellfish, meat, eggs, and dairy products
bProteins from the following eight food groups were included in plant protein:
cereals, pulses, potatoes, confectionaries, fruits, vegetables, alcoholic
beverages, and non-alcoholic beverages
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to down-regulate diet induced inflammation, i.e., diet-
ary supplementation of soy protein significantly re-
duced plasma MCP-1, as well as insulin and TNF-α, in
high fat diet-fed mice [36], although the isolate used
was reported to contain isoflavones as well. Hence, syn-
thetic peptides derived putatively from soy protein were
found to inhibit MCP-1 expression when they were
added to LPS-induced human vascular endothelial cells
in vitro [37]. This suggests that such inhibition is
mediated by peptides generated in vivo by protease/
peptidases in the gut. Similarly, rice endosperm protein
could possibly reduce MCP-1 levels in vivo in the same
way as soy protein does. However, intergroup difference
in MCP-1 was only tendency and further accumulation
of evidence is required.
The tolerability of additional proteins in usual meals
should be discussed. In the present study, the amount
of rice endosperm protein added was 10 g/day, a dose
Table 4 Changes in the measurements and clinical parameters during the 4-week intervention
Outcomes Rice endosperm protein period (n = 18) Casein period (n = 18)
Baseline 4 weeks Changesa Baseline 4 weeks Changesa P-value****
Measurements
Body weight (kg) 74.9 ± 11.6 74.6 ± 11.4 0.0 [−0.9, 0.5] 74.5 ± 11.1 74.8 ± 11.5 0.0 [−0.4, 0.5] 0.392
BMI (kg/m2) 25.4 ± 2.3 25.3 ± 2.3 0.0 [−0.3, 0.2] 25.2 ± 2.2 25.3 ± 2.3 0.0 [−0.1, 0.2] 0.231
Waist circumference (cm) 91.2 ± 6.4 90.8 ± 6.6 −1.0 [−1.0, 1.0] 91.3 ± 6.8 90.4 ± 6.4 −1.5 [−2.0, 0.0]* 0.473
SBP (mmHg) 124.2 ± 9.9 126.9 ± 10.3 4.0 [−3.0, 7.5] 126.6 ± 11.0 127.3 ± 15.0 0.0 [−6.0, 4.0] 0.825
DBP (mmHg) 79.6 ± 8.3 82.6 ± 6.3 4.0 [0.5, 6.0]** 79.8 ± 6.8 83.0 ± 9.4 3.0 [−3.5, 9.0] 0.722
Clinical parametersb
TC (mmol/L) 5.17 ± 0.90 5.15 ± 0.78 −0.10 [−0.23, 0.20] 5.24 ± 0.75 5.20 ± 0.87 −0.12 [−0.23, 0.19] 0.895
HDL-C (mmol/L) 1.20 ± 0.22 1.28 ± 0.26 0.08 [−0.05, 0.19]** 1.27 ± 0.27 1.22 ± 0.23 −0.04 [−0.13, 0.05] 0.047
HDL2 (mmol/L) 0.83 ± 0.25 0.87 ± 0.26 0.06 [−0.02, 0.14] 0.83 ± 0.24 0.84 ± 0.26 −0.02 [−0.06, 0.05] 0.145
HDL3 (mmol/L) 0.51 ± 0.08 0.54 ± 0.07 0.04 [−0.01, 0.08] 0.54 ± 0.08 0.53 ± 0.09 −0.01 [−0.06, 0.02] 0.122
LDL-C (mmol/L) 3.14 ± 0.70 3.20 ± 0.71 −0.04 [−0.32, 0.32] 3.24 ± 0.66 3.11 ± 0.70 −0.13 [−0.35, 0.12] 0.791
ApoA1 (g/L) 1.33 ± 0.20 1.37 ± 0.21 0.00 [−0.05, 0.08] 1.39 ± 0.21 1.34 ± 0.20 −0.02 [−0.14, 0.04] 0.331
ApoA2 (g/L) 0.31 ± 0.04 0.31 ± 0.03 0.00 [−0.02, 0.01] 0.31 ± 0.03 0.31 ± 0.04 0.00 [−0.02, 0.01] 0.895
ApoB (g/L) 1.03 ± 0.22 1.03 ± 0.20 −0.04 [−0.08, 0.05] 1.04 ± 0.20 1.03 ± 0.21 −0.01 [−0.07, 0.01] 0.791
ApoC2 (mg/L) 46 ± 25 44 ± 20 −1 [−8, 5] 48 ± 22 46 ± 24 −4 [−9, 3] 0.860
ApoC3 (mg/L) 114 ± 53 109 ± 30 9 [−29, 24] 116 ± 40 118 ± 52 −3 [−16, 21] 0.691
ApoE (mg/L) 48 ± 20 45 ± 10 0 [−6, 5] 48 ± 14 49 ± 19 −1 [−3, 3] 0.724
ox-LDL (IU/L) 151 ± 43 145 ± 41 −4 [−26, 20] 158 ± 43 143 ± 37 −16 [−27, −6]** 0.825
RLP-C (mg/L) 98 ± 178 56 ± 28 −4 [−18, 13] 69 ± 70 106 ± 178 0 [−15, 23] 0.269
hsCRP (mg/L) 0.98 ± 1.04 0.88 ± 0.94 −0.01 [−0.46, 0.43] 0.90 ± 1.08 1.21 ± 1.69 0.06 [−0.10, 0.47] 0.627
TG (mmol/L) 2.13 ± 2.20 1.76 ± 0.74 0.04 [−0.53, 0.55] 1.95 ± 1.34 2.34 ± 2.19 −0.05 [−0.17, 0.88] 0.508
Glucose (mmol/L) 5.20 ± 0.58 5.29 ± 0.83 0.06 [−0.12, 0.33] 5.24 ± 0.75 5.25 ± 0.58 0.06 [−0.26, 0.28] 0.595
Insulin (pmol/L) 54 ± 24 59 ± 32 −0.8 [−5.9, 24.3] 61 ± 52 59 ± 25 3.5 [−11.5, 23.9] 0.757
Adiponectin (mg/L) 6.6 ± 2.9 6.6 ± 2.7 0.2 [−0.5, 0.4] 6.5 ± 2.6 6.8 ± 2.6 0.1 [−0.3, 0.5] 0.627
UA (μmol/L) 379 ± 98 354 ± 91 −24 [−39, −6]*** 362 ± 97 362 ± 81 0 [−6, 13] 0.030
UN (mmol/L) 5.12 ± 0.77 5.20 ± 0.80 −0.04 [−0.44, 0.55] 4.98 ± 0.71 5.30 ± 0.89 0.29 [−0.37, 1.19] 0.402
CRE (μmol/dL) 70 ± 9 72 ± 9 2 [−1, 5] 70 ± 8 73 ± 9 2 [−1, 4]** 0.894
MCP-1 (ng/L) 311 ± 92 262 ± 83 −48 [−86, −9]*** 283 ± 85 283 ± 107 −6 [−52, 41] 0.058
Values for baseline and 4 weeks are indicated as Means ± SD
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL high density-lipoprotein, LDL low density lipoprotein,
Apo apolipoprotein, ox-LDL oxidized-LDL, RLP-C remnant like protein cholesterol, hsCRP high resolution C-peptide reactive protein, TG triglycerides, UA uric
acid, UN urea nitrogen, CRE creatinine, MCP-1 monocyte chemoattractant protein-1
aChanges in values over time are indicated as medians and interquartile ranges are shown in parenthesis. Significant differences and tendencies between values
over time are as follows: *P < 0.1, **P < 0.05, and ***P < 0.01; these differences were obtained using the Wilcoxon signed-rank test
****P -values of treatment effects are indicated. Values less than 0.1 were emphasized by bold letter
bAll clinical parameters indicate concentrations in serum
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much lower than the dose associated with harmful
effects advocated by Pedersen et al. [38] and the 23 g of
egg protein/day used in the study conducted by Asato
et al. [20]. Recent clinical trials with soy protein were
performed using doses of 15–56 g of protein/day [39–42];
however to date, no clinical reports have investigated rice
protein intake. Consequently, in the present study, we
used a smaller amount of protein, i.e., 10 g/day, to avoid
potential health hazards. Based on the BDHQ results, the
mean dietary protein intake was 1.05–1.11 g/kg BW/day
(Table 3). When the additional protein intake from the
intervention is taken into account, the resulting protein
intake was 1.18–1.24 g/kg BW/day. The dose of 10 g/day
of rice endosperm protein was found to be safe because
no adverse event related to the intake of study foods was
observed throughout the study.
A limitation of this study is that it included only men
with a relatively wide range in age who had a risk of
developing metabolic syndrome. In addition, the study
included only 18 subjects and the intervention lasted
only for 4 weeks. Although including a larger number
of subjects that included women would have provided
more robust results, due to the limitation of time and
resources, only men were enrolled. Furthermore, no
significant differences in SBP and DBP were observed
between groups. DBP in both groups had a tendency to
increase after 4 weeks, probably because of the environ-
mental conditions. Indeed, the final medical investiga-
tion at week 8 was performed on a very cold day in
December. Another limitation is the considerable short
washout period of 3 days. Although no treatment-
period interaction was detected as described before,
carryover effects cannot be excluded. Finally, we assessed
many outcome measures simultaneously since this study
was as an exploratory one. Consequently, some statistical
significance could have been observed by chance (type 1
error) and these results need to be further validated. The
future validation studies should take into account the
present obtained data for planning purposes. Despite these
limitations, the present study provides an important
insight into the beneficial effects of rice endosperm pro-
tein and a basis for future studies to examine long-term
effects in a larger number of participants including both
sexes.
Conclusion
Rice endosperm protein intake may increase HDL-C as
well as reduce serum UA level in adult male subjects
with risk factors for metabolic syndrome. These findings
would suggest the beneficial effect of rice endosperm
protein intake in prevention of incidence or suppression
of deterioration of metabolic syndrome, and consequent
reduction of risk for cardiovascular events, although
further detailed study is required.
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